KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Gross Profit (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Gross Profit data on record, last reported at $156.6 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 6.25% year-over-year to $156.6 million; the TTM value through Dec 2025 reached $576.7 million, up 8.69%, while the annual FY2025 figure was $576.7 million, 8.69% up from the prior year.
  • Gross Profit reached $156.6 million in Q4 2025 per PCRX's latest filing, up from $145.2 million in the prior quarter.
  • Across five years, Gross Profit topped out at $156.6 million in Q4 2025 and bottomed at $87.7 million in Q1 2021.
  • Average Gross Profit over 5 years is $123.2 million, with a median of $121.6 million recorded in 2022.
  • Peak YoY movement for Gross Profit: surged 88.61% in 2021, then dropped 10.67% in 2022.
  • A 5-year view of Gross Profit shows it stood at $120.2 million in 2021, then decreased by 10.67% to $107.4 million in 2022, then grew by 24.39% to $133.6 million in 2023, then increased by 10.34% to $147.4 million in 2024, then rose by 6.25% to $156.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $156.6 million in Q4 2025, $145.2 million in Q3 2025, and $140.2 million in Q2 2025.